Abstract
Keloids are the result of excessive scar tissue formation. Besides their poor aesthetic appearance, keloids can be associated with severe clinical symptoms such as pain, itching, and rigidity. Unfortunately, most therapeutic approaches remain clinically unsatisfactory. Recently, injections with botulinum toxin A (BTA) were proposed for the treatment of established keloids in a clinical trial. In this study, we aimed to verify the effects of intralesional BTA for the treatment of therapy-resistant keloids using objective measurements. In addition, the underlying molecular mechanisms were investigated using cultured keloid-derived fibroblasts.
Original language | English |
---|---|
Pages (from-to) | 313-8 |
Number of pages | 6 |
Journal | Skin pharmacology and physiology |
Volume | 25 |
Issue number | 6 |
DOIs | |
Publication status | Published - 2012 |
Bibliographical note
Copyright © 2012 S. Karger AG, Basel.Keywords
- Actins
- Botulinum Toxins, Type A
- Cell Proliferation
- Collagen
- Female
- Fibroblasts
- Fibronectins
- Humans
- Injections, Intralesional
- Keloid
- Laminin
- Male
- Transforming Growth Factor beta